K1_VACCW
ID K1_VACCW Reviewed; 284 AA.
AC P04297; Q85352;
DT 20-MAR-1987, integrated into UniProtKB/Swiss-Prot.
DT 07-DEC-2004, sequence version 2.
DT 23-FEB-2022, entry version 90.
DE RecName: Full=Interferon antagonist K1L;
DE AltName: Full=32.5 kDa protein;
DE AltName: Full=Host range protein 1;
GN OrderedLocusNames=VACWR032; ORFNames=K1L;
OS Vaccinia virus (strain Western Reserve) (VACV) (Vaccinia virus (strain
OS WR)).
OC Viruses; Varidnaviria; Bamfordvirae; Nucleocytoviricota; Pokkesviricetes;
OC Chitovirales; Poxviridae; Chordopoxvirinae; Orthopoxvirus; Vaccinia virus.
OX NCBI_TaxID=10254;
OH NCBI_TaxID=9913; Bos taurus (Bovine).
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX PubMed=3461450; DOI=10.1073/pnas.83.15.5573;
RA Gillard S., Spehner D., Drillien R., Kirn A.;
RT "Localization and sequence of a vaccinia virus gene required for
RT multiplication in human cells.";
RL Proc. Natl. Acad. Sci. U.S.A. 83:5573-5577(1986).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX PubMed=2719552; DOI=10.1007/bf01311113;
RA Altenburger W., Suter C.P., Altenburger J.;
RT "Partial deletion of the human host range gene in the attenuated vaccinia
RT virus MVA.";
RL Arch. Virol. 105:15-27(1989).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA Esposito J.J., Frace A.M., Sammons S.A., Olsen-Rasmussen M., Osborne J.,
RA Wohlhueter R.;
RT "Sequencing of the coding region of Vaccinia-WR to an average 9-fold
RT redundancy and an error rate of 0.16/10kb.";
RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-17.
RX PubMed=3264331; DOI=10.1099/0022-1317-69-12-2995;
RA Boursnell M.E.G., Foulds I.J., Campbell J.I., Binns M.M.;
RT "Non-essential genes in the vaccinia virus HindIII K fragment: a gene
RT related to serine protease inhibitors and a gene related to the 37K
RT vaccinia virus major envelope antigen.";
RL J. Gen. Virol. 69:2995-3003(1988).
RN [5]
RP FUNCTION.
RX PubMed=19656868; DOI=10.1128/jvi.01260-09;
RA Meng X., Jiang C., Arsenio J., Dick K., Cao J., Xiang Y.;
RT "Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I
RT interferons.";
RL J. Virol. 83:10627-10636(2009).
RN [6]
RP FUNCTION.
RX PubMed=20089642; DOI=10.1128/jvi.02332-09;
RA Li Y., Meng X., Xiang Y., Deng J.;
RT "Structure function studies of vaccinia virus host range protein k1 reveal
RT a novel functional surface for ankyrin repeat proteins.";
RL J. Virol. 84:3331-3338(2010).
RN [7]
RP FUNCTION.
RX PubMed=21183678; DOI=10.1074/jbc.m110.194704;
RA Willis K.L., Langland J.O., Shisler J.L.;
RT "Viral double-stranded RNAs from vaccinia virus early or intermediate gene
RT transcripts possess PKR activating function, resulting in NF-kappaB
RT activation, when the K1 protein is absent or mutated.";
RL J. Biol. Chem. 286:7765-7778(2011).
RN [8]
RP FUNCTION, AND SUBCELLULAR LOCATION.
RX PubMed=27503790; DOI=10.1099/jgv.0.000576;
RA Bravo Cruz A.G., Shisler J.L.;
RT "Vaccinia virus K1 ankyrin repeat protein inhibits NF-kappaB activation by
RT preventing RelA acetylation.";
RL J. Gen. Virol. 97:2691-2702(2016).
CC -!- FUNCTION: Inhibits antiviral activity induced by type I interferons.
CC Does not block signal transduction of IFN, but is important to counter
CC the host antiviral state induced by a pre-treatment with IFN. Plays a
CC role in the inhibition of host NF-kappa-B activation by preventing the
CC acetylation of the RELA/p65 subunit of NF-kappaB.
CC {ECO:0000269|PubMed:19656868, ECO:0000269|PubMed:20089642,
CC ECO:0000269|PubMed:21183678, ECO:0000269|PubMed:27503790}.
CC -!- SUBCELLULAR LOCATION: Host cytoplasm {ECO:0000269|PubMed:27503790}.
CC Host nucleus {ECO:0000269|PubMed:27503790}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; D00382; BAA00286.1; -; Genomic_DNA.
DR EMBL; M27648; AAA69633.1; -; Genomic_DNA.
DR EMBL; AY243312; AAO89311.1; -; Genomic_DNA.
DR EMBL; M14319; AAA48299.1; -; Genomic_DNA.
DR PIR; A03868; WMVZ32.
DR RefSeq; YP_232914.1; NC_006998.1.
DR SMR; P04297; -.
DR IntAct; P04297; 3.
DR MINT; P04297; -.
DR DNASU; 3707647; -.
DR GeneID; 3707647; -.
DR KEGG; vg:3707647; -.
DR Proteomes; UP000000344; Genome.
DR GO; GO:0030430; C:host cell cytoplasm; IDA:UniProtKB.
DR GO; GO:0042025; C:host cell nucleus; IDA:UniProtKB.
DR GO; GO:0039503; P:suppression by virus of host innate immune response; IEA:UniProtKB-KW.
DR GO; GO:0039644; P:suppression by virus of host NF-kappaB cascade; IDA:UniProtKB.
DR Gene3D; 1.25.40.20; -; 1.
DR InterPro; IPR002110; Ankyrin_rpt.
DR InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR Pfam; PF12796; Ank_2; 1.
DR SMART; SM00248; ANK; 6.
DR SUPFAM; SSF48403; SSF48403; 1.
DR PROSITE; PS50297; ANK_REP_REGION; 1.
DR PROSITE; PS50088; ANK_REPEAT; 2.
PE 4: Predicted;
KW ANK repeat; Early protein; Host cytoplasm; Host nucleus;
KW Host-virus interaction; Inhibition of host innate immune response by virus;
KW Inhibition of host NF-kappa-B by virus; Reference proteome; Repeat;
KW Viral immunoevasion.
FT CHAIN 1..284
FT /note="Interferon antagonist K1L"
FT /id="PRO_0000067081"
FT REPEAT 29..58
FT /note="ANK 1"
FT REPEAT 60..89
FT /note="ANK 2"
FT REPEAT 93..122
FT /note="ANK 3"
FT REPEAT 127..157
FT /note="ANK 4"
FT REPEAT 159..188
FT /note="ANK 5"
FT REPEAT 193..222
FT /note="ANK 6"
FT CONFLICT 23
FT /note="A -> T (in Ref. 1; AAA48299)"
FT /evidence="ECO:0000305"
FT CONFLICT 85
FT /note="L -> M (in Ref. 1; AAA48299)"
FT /evidence="ECO:0000305"
FT CONFLICT 166
FT /note="I -> T (in Ref. 1; AAA48299)"
FT /evidence="ECO:0000305"
FT CONFLICT 223
FT /note="A -> V (in Ref. 1; AAA48299)"
FT /evidence="ECO:0000305"
FT CONFLICT 236
FT /note="A -> T (in Ref. 1; AAA48299)"
FT /evidence="ECO:0000305"
FT CONFLICT 243
FT /note="H -> D (in Ref. 1; AAA48299)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 284 AA; 32467 MW; 6B4F6C907DBE0C10 CRC64;
MDLSRINTWK SKQLKSFLSS KDAFKADVHG HSALYYAIAD NNVRLVCTLL NAGALKNLLE
NEFPLHQAAT LEDTKIVKIL LFSGLDDSQF DDKGNTALYY AVDSGNMQTV KLFVKKNWRL
MFYGKTGWKT SFYHAVMLND VSIVSYFLSE IPSTFDLAIL LSCIHITIKN GHVDMMILLL
DYMTSTNTNN SLLFIPDIKL AIDNKDIEML QALFKYDINI YSANLENVLL DDAEIAKMII
EKHVEYKSDS YTKDLDIVKN NKLDEIISKN KELRLMYVNC VKKN
